Cargando…

Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics

Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries. Lifestyle or diet, environmental pollutants, genetics, gut dysbiosis, neuroendocrine alterations, and obesity are...

Descripción completa

Detalles Bibliográficos
Autores principales: Singh, Samradhi, Pal, Namrata, Shubham, Swasti, Sarma, Devojit Kumar, Verma, Vinod, Marotta, Francesco, Kumar, Manoj
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964744/
https://www.ncbi.nlm.nih.gov/pubmed/36835989
http://dx.doi.org/10.3390/jcm12041454
_version_ 1784896584021966848
author Singh, Samradhi
Pal, Namrata
Shubham, Swasti
Sarma, Devojit Kumar
Verma, Vinod
Marotta, Francesco
Kumar, Manoj
author_facet Singh, Samradhi
Pal, Namrata
Shubham, Swasti
Sarma, Devojit Kumar
Verma, Vinod
Marotta, Francesco
Kumar, Manoj
author_sort Singh, Samradhi
collection PubMed
description Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries. Lifestyle or diet, environmental pollutants, genetics, gut dysbiosis, neuroendocrine alterations, and obesity are among the risk factors that predispose females to PCOS. These factors might contribute to upsurging metabolic syndrome by causing hyperinsulinemia, oxidative stress, hyperandrogenism, impaired folliculogenesis, and irregular menstrual cycles. Dysbiosis of gut microbiota may play a pathogenic role in the development of PCOS. The restoration of gut microbiota by probiotics, prebiotics, or a fecal microbiota transplant (FMT) might serve as an innovative, efficient, and noninvasive way to prevent and mitigate PCOS. This review deliberates on the variety of risk factors potentially involved in the etiology, prevalence, and modulation of PCOS, in addition to plausible therapeutic interventions, including miRNA therapy and the eubiosis of gut microbiota, that may help treat and manage PCOS.
format Online
Article
Text
id pubmed-9964744
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99647442023-02-26 Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics Singh, Samradhi Pal, Namrata Shubham, Swasti Sarma, Devojit Kumar Verma, Vinod Marotta, Francesco Kumar, Manoj J Clin Med Review Polycystic ovary syndrome (PCOS) is a complex endocrine and metabolic disorder, typically characterized by anovulation, infertility, obesity, insulin resistance, and polycystic ovaries. Lifestyle or diet, environmental pollutants, genetics, gut dysbiosis, neuroendocrine alterations, and obesity are among the risk factors that predispose females to PCOS. These factors might contribute to upsurging metabolic syndrome by causing hyperinsulinemia, oxidative stress, hyperandrogenism, impaired folliculogenesis, and irregular menstrual cycles. Dysbiosis of gut microbiota may play a pathogenic role in the development of PCOS. The restoration of gut microbiota by probiotics, prebiotics, or a fecal microbiota transplant (FMT) might serve as an innovative, efficient, and noninvasive way to prevent and mitigate PCOS. This review deliberates on the variety of risk factors potentially involved in the etiology, prevalence, and modulation of PCOS, in addition to plausible therapeutic interventions, including miRNA therapy and the eubiosis of gut microbiota, that may help treat and manage PCOS. MDPI 2023-02-11 /pmc/articles/PMC9964744/ /pubmed/36835989 http://dx.doi.org/10.3390/jcm12041454 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Singh, Samradhi
Pal, Namrata
Shubham, Swasti
Sarma, Devojit Kumar
Verma, Vinod
Marotta, Francesco
Kumar, Manoj
Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
title Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
title_full Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
title_fullStr Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
title_full_unstemmed Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
title_short Polycystic Ovary Syndrome: Etiology, Current Management, and Future Therapeutics
title_sort polycystic ovary syndrome: etiology, current management, and future therapeutics
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9964744/
https://www.ncbi.nlm.nih.gov/pubmed/36835989
http://dx.doi.org/10.3390/jcm12041454
work_keys_str_mv AT singhsamradhi polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics
AT palnamrata polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics
AT shubhamswasti polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics
AT sarmadevojitkumar polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics
AT vermavinod polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics
AT marottafrancesco polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics
AT kumarmanoj polycysticovarysyndromeetiologycurrentmanagementandfuturetherapeutics